Multivariate model for overall and disease-free survival
| Factor . | HR (95% CI) . | P . | ||
|---|---|---|---|---|
| Overall survival, best-fit model | ||||
| Tumor size (T1, T2, T3) | 1.98 (1.31–3.01) | 0.001 | ||
| Axillary node status (0, 1–3, ≥4) | 1.84 (1.21–2.81) | 0.004 | ||
| β1 integrin intensity score (0, 1, 2, 3) | 1.73 (1.22–2.44) | 0.002 | ||
| Disease-free survival, best-fit model | ||||
| Tumor size (T1, T2, T3) | 3.86 (2.18–6.81) | 0.000 | ||
| SBR score (1, 2, 3) | 2.24 (1.10–4.53) | 0.025 | ||
| β1 integrin intensity score (0, 1, 2, 3) | 1.88 (1.20–2.95) | 0.006 | ||
| Age | 0.95 (0.92–0.99) | 0.007 | ||
| Chemotherapy | 0.33 (0.12–0.89) | 0.030 | ||
| Factor . | HR (95% CI) . | P . | ||
|---|---|---|---|---|
| Overall survival, best-fit model | ||||
| Tumor size (T1, T2, T3) | 1.98 (1.31–3.01) | 0.001 | ||
| Axillary node status (0, 1–3, ≥4) | 1.84 (1.21–2.81) | 0.004 | ||
| β1 integrin intensity score (0, 1, 2, 3) | 1.73 (1.22–2.44) | 0.002 | ||
| Disease-free survival, best-fit model | ||||
| Tumor size (T1, T2, T3) | 3.86 (2.18–6.81) | 0.000 | ||
| SBR score (1, 2, 3) | 2.24 (1.10–4.53) | 0.025 | ||
| β1 integrin intensity score (0, 1, 2, 3) | 1.88 (1.20–2.95) | 0.006 | ||
| Age | 0.95 (0.92–0.99) | 0.007 | ||
| Chemotherapy | 0.33 (0.12–0.89) | 0.030 | ||